LINEAGE CELL THERAPEUTICS IN's ticker is LCTX and the CUSIP is 53566P109. A total of 116 filers reported holding LINEAGE CELL THERAPEUTICS IN in Q1 2023. The put-call ratio across all filers is 0.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $119,534 | -16.3% | 101,300 | 0.0% | 0.00% | 0.0% |
Q2 2023 | $142,833 | -6.0% | 101,300 | 0.0% | 0.00% | 0.0% |
Q1 2023 | $151,950 | +28.2% | 101,300 | 0.0% | 0.00% | 0.0% |
Q4 2022 | $118,521 | +4.0% | 101,300 | 0.0% | 0.00% | 0.0% |
Q3 2022 | $114,000 | -28.8% | 101,300 | 0.0% | 0.00% | -33.3% |
Q2 2022 | $160,000 | +2.6% | 101,300 | 0.0% | 0.00% | +50.0% |
Q1 2022 | $156,000 | -37.1% | 101,300 | 0.0% | 0.00% | -33.3% |
Q4 2021 | $248,000 | +4.2% | 101,300 | 0.0% | 0.00% | -25.0% |
Q1 2021 | $238,000 | +33.7% | 101,300 | 0.0% | 0.00% | +33.3% |
Q4 2020 | $178,000 | +87.4% | 101,300 | 0.0% | 0.00% | +50.0% |
Q3 2020 | $95,000 | +8.0% | 101,300 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $88,000 | +4.8% | 101,300 | 0.0% | 0.00% | 0.0% |
Q1 2020 | $84,000 | -6.7% | 101,300 | 0.0% | 0.00% | 0.0% |
Q4 2019 | $90,000 | -10.0% | 101,300 | -0.4% | 0.00% | 0.0% |
Q3 2019 | $100,000 | – | 101,661 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
BROADWOOD CAPITAL INC | 34,935,485 | $40,874,517 | 3.42% |
Defender Capital, LLC. | 5,093,535 | $5,959,436 | 2.41% |
Raffles Associates | 1,536,946 | $1,798,230 | 2.10% |
Prescott General Partners LLC | 1,851,851 | $2,166,666 | 0.18% |
DAFNA Capital Management LLC | 140,000 | $163,800 | 0.05% |
Fort Sheridan Advisors LLC | 83,931 | $98,199 | 0.03% |
Beirne Wealth Consulting Services, LLC | 45,000 | $52,650 | 0.03% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 781,766 | $914,666 | 0.02% |
ETF MANAGERS GROUP, LLC | 353,991 | $414,169 | 0.02% |
Straight Path Wealth Management | 16,200 | $18,954 | 0.02% |